

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: E24/17 - Hormones 2

Dead line: 24.10.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability											
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>
<b>(193) Ferritin</b>					25						23	23	100%
Samples and groups	[µg/L]												
<b>Sample A</b>		96,0	15	16	25						23	23	100%
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		116	1,5	1,3	5	0	CVPG	114	1,6	24%	86,6	142	5
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		101	3,4	3,4	5	0	CVPG	104	1,3	24%	79	129	5
Other					15	0							13
								4x 4/12, 1x 4/149, 3x 4/179, 2x 6/58, 3x 6/60, 2x 6/178					
<b>Sample B</b>		87,3	12	14	25						23	23	100%
(4) LIA (CLIA, CMIA, ILMA); (1) Abbott		95,5	6,3	6,6	5	0	CVPG	95,1	1,3	24%	72,2	118	5
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		98,8	4,2	4,2	5	0	CVPG	97	1,1	24%	73,7	121	5
Other					15	0							13
								4x 4/12, 1x 4/149, 3x 4/179, 2x 6/58, 3x 6/60, 2x 6/178					
<b>(320) LH</b>					20						20	20	100%
Samples and groups	[U/L]												
<b>Sample A</b>		28,3	7,3	26	20						20	20	100%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		21,3	1,9	9,0	8	0	CVPG	21,9	0,34	15%	18,6	25,2	8
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		34,1	0,90	2,7	5	0	CVPG	34,3	0,20	15%	29,1	39,5	5
Other					7	0							7
								1x 3/25, 2x 4/1, 1x 4/29, 1x 4/149, 2x 4/179					
<b>Sample B</b>		18,0	5,7	32	20						20	20	100%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		12,5	0,73	5,9	8	0	CVPG	13	0,23	15%	11	15	8
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		22,5	0,94	4,2	5	0	CVPG	22,8	0,13	15%	19,3	26,3	5
Other					7	0							7
								1x 3/25, 2x 4/1, 1x 4/29, 1x 4/149, 2x 4/179					
<b>(321) FSH</b>					20						20	19	95%
Samples and groups	[U/L]												
<b>Sample A</b>		26,3	2,7	10	20						20	19	95%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		25,4	3,9	15	8	0	CVPG	25	0,42	15%	21,2	28,8	8
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		27,3	0,31	1,1	5	0	CVPG	26,5	0,17	15%	22,5	30,5	5
Other					7	0							7
								1x 3/25, 2x 4/1, 1x 4/29, 1x 4/149, 2x 4/179					
<b>Sample B</b>		9,45	1,1	12	20						20	20	100%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		8,70	0,93	11	8	0	CVPG	8,91	0,14	15%	7,57	10,3	8
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		10,2	0,13	1,2	5	0	CVPG	9,87	0,062	15%	8,38	11,4	5
Other					7	0							7
								1x 3/25, 2x 4/1, 1x 4/29, 1x 4/149, 2x 4/179					
<b>(322) Prolactin</b>					21						20	18	90%
Samples and groups	[mU/L]												
<b>Sample A</b>		559	63	11	21						20	18	90%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		530	42	7,9	7	0	CVPG	523	9,4	16%	439	607	7
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		601	54	9,0	5	0	CVPG	608	3,9	16%	510	706	5
Other					9	0							8
								1x 1/36, 1x 3/25, 1x 4/1, 2x 4/29, 1x 4/149, 3x 4/179					
<b>Sample B</b>		152	26	17	21						20	19	95%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		138	10	7,5	7	0	CVPG	139	2,4	16%	116	162	7
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		180	12	6,5	5	0	CVPG	184	1,2	16%	154	214	5
Other					9	0							8
								1x 1/36, 1x 3/25, 1x 4/1, 2x 4/29, 1x 4/149, 3x 4/179					
<b>(325) Insulin</b>					10						9	9	100%
Samples and groups	[mU/L]												
<b>Sample A</b>		80,1	9,9	12	10						9	9	100%
Other					10	0							9
								1x 1/36, 4x 4/1, 3x 4/60, 2x 4/179					
<b>Sample B</b>		19,8	3,1	16	10						9	9	100%
Other					10	0							9
								1x 1/36, 4x 4/1, 3x 4/60, 2x 4/179					

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: E24/17 - Hormones 2

Dead line: 24.10.2017

Test	[unit]						Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(326) Folate</b>					24							24	17	71%	
Samples and groups	[nmol/L]														
<b>Sample A</b>		5,60	1,6	29	24							24	18	75%	
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		7,15	1,1	16	6	0	CVPG	6,52	0,14	27%	4,75	8,29	6		
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		5,21	0,95	18	10	0	CVPG	4,38	0,099	±1,35	3,03	5,73	10		
Other					8	0							8		
								4x 4/1, 1x 4/149, 3x 4/179							
<b>Sample B</b>		25,7	4,6	18	24							24	21	88%	
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		29,8	1,8	6,2	6	0	CVPG	29	0,42	27%	21,1	36,9	6		
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		24,4	3,5	14	10	0	CVPG	22,2	0,25	27%	16,2	28,2	10		
Other					8	0							8		
								4x 4/1, 1x 4/149, 3x 4/179							
<b>(327) Vitamin B12</b>					25							25	21	84%	
Samples and groups	[pmol/L]														
<b>Sample A</b>		242	43	18	25							25	22	88%	
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		191	16	8,5	6	0	CVPG	184	3,4	20%	147	221	6		
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		262	35	13	10	0	CVPG	255	2,4	20%	204	306	10		
Other					9	0							9		
								4x 4/1, 1x 4/29, 1x 4/149, 3x 4/179							
<b>Sample B</b>		602	80	13	25							25	21	84%	
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		514	27	5,3	6	0	CVPG	491	10,0	20%	392	590	6		
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		636	78	12	10	0	CVPG	604	4,0	20%	483	725	10		
Other					9	0							9		
								4x 4/1, 1x 4/29, 1x 4/149, 3x 4/179							
<b>(328) hGH</b>					8							8	8	100%	
Samples and groups	[mU/L]														
<b>Sample A</b>		30,0	3,1	10	8							8	8	100%	
Other					8	0							8		
								1x 1/36, 2x 4/12, 4x 4/29, 1x 4/60							
<b>Sample B</b>		4,99	0,96	19	8							8	8	100%	
Other					8	0							8		
								1x 1/36, 2x 4/12, 4x 4/29, 1x 4/60							
<b>(329) IGF-1</b>					5							5	5	100%	
Samples and groups	[µg/L]														
<b>Sample A</b>		164	1,9	1,1	5							5	5	100%	
Other					5	0							5		
								1x 1/36, 4x 4/29							
<b>Sample B</b>		146	5,9	4,1	5							5	5	100%	
Other					5	0							5		
								1x 1/36, 4x 4/29							
<b>(390) Renin</b>					3							2	2	100%	
Samples and groups	[ng/L]														
<b>Sample A</b>		37,9	4,1	11	3							2	2	100%	
Other					3	0							2		
								1x 1/185, 1x 2/66, 1x 4/164							
<b>Sample B</b>		45,5	6,3	14	3							2	2	100%	
Other					3	0							2		
								1x 1/185, 1x 2/66, 1x 4/164							
<b>(392) IGF-BP3</b>					2							1	1	100%	
Samples and groups	[µg/L]														
<b>Sample A</b>		3120	1000	33	2							1	1	100%	
Other					2	0							1		
								1x 1/183, 1x 4/29							
<b>Sample B</b>		2950	950	32	2							1	1	100%	
Other					2	0							1		
								1x 1/183, 1x 4/29							
<b>(393) C-peptide</b>					16							15	15	100%	
Samples and groups	[pmol/L]														
<b>Sample A</b>		328	67	20	16							15	15	100%	
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		382	12	3,2	7	0	CVPG	386	7,5	20%	308	464	7		
Other					9	0							8		
								1x 1/36, 3x 4/1, 2x 4/29, 3x 4/179							
<b>Sample B</b>		152	35	23	16							15	15	100%	
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		185	7,4	4,0	7	0	CVPG	183	3,4	20%	146	220	7		
Other					9	0							8		
								1x 1/36, 3x 4/1, 2x 4/29, 3x 4/179							

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of groups n = 5

## EQA round: E24/17 - Hormones 2

Dead line: 24.10.2017

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability							
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(394) SHBG</b>					10							10	10	100%
Samples and groups	[nmol/L]													
<b>Sample A</b>		119	20	17	10							10	10	100%
Other					10	0						10		
							2x 4/1, 2x 4/12, 2x 4/29, 4x 4/60							
<b>Sample B</b>		32,3	4,0	12	10							10	10	100%
Other					10	0						10		
							2x 4/1, 2x 4/12, 2x 4/29, 4x 4/60							
<b>(405) Parathyroid hormone (PTH)</b>					22							22	16	73%
Samples and groups	[pmol/L]													
<b>Sample A</b>		0,964	0,41	43	22							22	17	77%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		0,630	0,059	9,4	5	0	CVPG	0,63	0,029 ± 0,276	0,354	0,906	5		
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		1,18	0,28	24	13	0	CVPG	1,1	0,025 ± 0,28	0,824	1,38	13		
Other					4	1						4		
							1x 4/1, 2x 4/29, 1x 4/179							
<b>Sample B</b>		20,5	4,5	22	22							22	20	91%
(4) LIA (CLIA, CMIA, ILMA); (12) Beckman Coulter		21,1	1,3	6,0	5	0	CVPG	22,5	0,85	23%	17,3	27,7	5	
(4) LIA (CLIA, CMIA, ILMA); (60) Roche		18,8	1,9	10	13	0	CVPG	18,2	0,19	23%	14	22,4	13	
Other					4	0						4		
							1x 4/1, 2x 4/29, 1x 4/179							

st\_kn\_p

End of report

Printed: 11.11.2017